Canada: Product Liability E-Communiqué - February 2015

In This Issue

  1. Charlton in Charge: BC Court of Appeal Overturns Pharmaceutical Class Action Certification Due to Plaintiff's Failure to Provide Workable Causation Methodology
  2. Files Exhibited, Fines Unlimited: Health Industry Risks Under the New Bill C-17
  3. Keeping You Up-To-Date on Consumer Product Regulation: What's New With The Canada Consumer Product Safety Act?

Charlton in Charge: BC Court of Appeal Overturns Pharmaceutical Class Action Certification Due to Plaintiff's Failure to Provide Workable Causation Methodology

By Christopher Horkins

Canadian courts may be taking a firmer stance against certification in pharmaceutical class actions. The recent decision of the British Columbia Court of Appeal setting aside the certification of a pharmaceutical class action in Charlton v. Abbott Laboratories Ltd. ("Charlton") provides evidence of a growing trend in favour of defendants in prescription drug class actions in Canada.1 Although the certification test in most Canadian jurisdictions remains a procedural question, it is clear that courts will require plaintiffs to show that causation is capable of being proven on a class-wide basis before giving the green light to a proposed class action.

History of the Proceedings

The Charlton class action against pharmaceutical manufacturers Abbott Laboratories, Ltd. ("Abbott") and Apotex Inc. ("Apotex") was commenced on behalf of patients across Canada who had used or purchased the prescription drug sibutramine, alleging that the drug increased the risk of cardiovascular events such as heart attack and stroke. The plaintiffs alleged that the defendants were liable in negligence, waiver of tort and for breaches of Canada's Competition Act and British Columbia's Business Practices and Consumer Protection Act.

A weight-loss drug containing sibutramine was developed by Abbott and approved for use in Canada in late 2000. In 2009, Apotex began distributing a generic weight loss drug containing sibutramine. In 2010, a US medical journal published a study suggesting that sibutramine was associated with an increased risk of serious cardiovascular events for patients with pre-existing heart conditions. Shortly afterwards, the drugs were voluntarily taken off the Canadian market by Abbott and Apotex.

Decision of the BC Supreme Court

At first instance, the BC Supreme Court certified the action as a class proceeding under BC's Class Proceedings Act. The certification judge noted that his role was not to test the merits of the action, but rather to focus on the form of the action and whether it was appropriately prosecuted as a class action. Applying the low threshold "some basis in fact" test from the Supreme Court's leading decision in Hollick v. Toronto (City), the Court certified the proposed class action.

Decision of the BC Court of Appeal

On appeal, the BC Court of Appeal overturned the certification order, finding that the plaintiffs had failed to adduce evidence of a workable methodology to determine the issue of general, class-wide causation – namely, that sibutramine actually increased the risk of cardiovascular events for all class members. Since the only evidence before the Court was the study suggesting an increased risk for patients with pre-existing heart conditions, the Court found there was no viable methodology for determining causation with respect to the wider class:

While there is no dispute that those with pre-existing cardiopulmonary disease are at a statistically increased risk of adverse cardiac events, this is not a case where the experts disagree on the extent of the risk, but rather, a case where the experts are uncertain whether there is a risk to the class as a whole and cannot describe a methodology for addressing that question.

This was found to be a necessary element of proof for each of the certified common issues. As such, the question of causation was incapable of resolution based on the evidence at the certification hearing. Accordingly, the Court of Appeal found it was an error for the certification judge to have certified the class action and set aside the certification order.

Implications Going Forward

What can product liability class action defendants take away from this decision? It demonstrates how arguments relating to the merits can be imported into the certification test and used to defeat certification. As Justice Willcock stated: "The question that ought to have been asked at the certification hearing in relation to both types of claims, is not whether the resolution of the general causation question will advance the class claims, but rather, whether there is a reasonable prospect of doing so." The failure of plaintiff's counsel to put forward viable evidence of class-wide causation can be considered a failure to demonstrate causation on a class-wide basis and that a class action is the "preferable procedure."

Viewed together with the Ontario Divisional Court decision in Martin v. Astrazeneca (which we covered in our 2014 year-in-review), the Charlton decision demonstrates a shift to a stricter and more thorough analysis of proposed class action claims.

Files Exhibited, Fines Unlimited: Health Industry Risks Under the New Bill C-17

By Emily Larose and Jeremy Martin

The Minister of Health and Health Canada have bulked up with new powers over the holidays, and the medical products community needs to take notice.  On November 6, 2014, Bill C-17 ("the Bill") (also referred to as the Protecting Canadians from Unsafe Drugs Act or Vanessa's Law) received Royal Assent. The Bill amends the federal Food and Drugs Act, R.S.C. 1985, c. F-27 (the "Act") and imposes stricter regulations, reporting requirements, and penalties on the industry. The Bill was named after the daughter of MP Terence Young, who passed away following an adverse drug reaction.

The name of the Bill is a bit of a misnomer, as pharmaceuticals are only one of the regulated products affected. The Bill as a whole is concerned with the safety of "therapeutic products," which includes both pharmaceuticals and medical "devices,"2 but excludes natural health products.

Generally speaking, the changes compel the industry to operate with more public transparency and responsiveness to the regulator, and set out a series of penalties that can go so far as to target individuals for prosecution if they cause a company to step out of line.

Companies should obviously be implementing compliance reviews in light of these amendments, but thought should also be given to the potential implications of these amendments for product liability claims faced by industry.

Key Features of Vanessa's Law

The key features of Vanessa's Law are set out below. For a more comprehensive overview of the new amendments, please consult our previous elert on this topic.

1. Increased Powers of the Minister

Under Vanessa's Law, the Minister of Health ("the Minister") has broader authority to undertake investigations and to require reporting and study from the industry. Under the new law, the Minister may issue orders requiring industry participants to:

a) Provide specified information about a product;

b) Modify packaging or labelling;

c) Ship products to a specified location;

d) Undertake a recall, product assessment or other corrective action; or to

e) Conduct test, studies or monitoring.

The prerequisites for these orders will vary from situation to situation, but generally will require the Minister to have a reasonable belief that a product presents a serious or imminent risk of injury to human health.

2. Broadened Mandatory Reporting

The amended Act now provides for mandatory incident reports by "institutions." The definition of "institutions" has not yet been determined by regulation, and the threshold for and scope of those incident reports are still an open question. We expect, however, that these "institutions" will likely include hospitals, which may be required by future regulation to report adverse reactions to prescription medications to the Minister of Health. This is already a requirement in some European countries, and may be on its way to Canada.

3. Disclosure of Confidential Business Information

The amended Act gives the Minister the power to unilaterally disclose otherwise confidential business information about a product without the consent of that product's manufacturer where the Minister believes that the product may present a serious risk of injury to human health.  In some cases this can be done without notification either prior to, or after, the disclosure.

4. Additional and More Severe Penalties

Contraventions of the Act are now much more serious offences. The Act formerly set the punishment for an indictable offence at a maximum $5,000 fine and a jail term of three years.  That maximum has now been raised to $5 million and a term of two years.

The amendments also introduced an offence of knowingly or recklessly causing a serious risk of injury to human health, which carries a maximum penalty of an unlimited fine and a five year term of imprisonment.  These offences can apply to individuals (officers, directors, agents, employees, etc.) as well as to the company itself.

These new penalties are compounded by the new Section 31.7, which causes each day in which the industry participant continued the breach of the Act to constitute a new and separate chargeable offence, meaning that the penalties under the Act can be assigned, up to their maximum amount, again and again for each day the regulated company was not in compliance.

In addition to the existing obligations under the Food and Drugs Act, the amendments make it an offence to make a false or misleading statement about a therapeutic product to the Minister, although due diligence constitutes a defence.

5. New Regulation Making Powers

The amended Act also permits the making of regulations relating to post-marketing activities.  These new regulations may include a requirement that any industry participant may have to provide information with respect to its activities outside of Canada; permitting conditions to be placed on product authorizations; and requiring further transparency and disclosure with respect to clinical trial and investigational test information.

Product Liability Implications

It remains to be seen how Health Canada will use these new powers, and the extent to which that will change the landscape of product development and marketing in Canada. We will also be carefully tracking whether there is an impact on the number and type of product liability claims brought against our clients.

Depending on the nature of the regulations still to be released and the manner in which Health Canada chooses to implement them, we can foresee some likely changes in the legal landscape of the industry with respect to product liability:

  • If the new regulations result in an increase in recalls, there may well be a correlative increase in class action claims, which in Canada frequently follow any significant recall of a pharmaceutical product.
  • Similarly, if these amendments result in prosecutions (which are currently quite rare under the Food and Drugs Act), a finding that an offence has been committed in respect of a therapeutic product is also likely to attract the interest of plaintiffs' lawyers.
  • We also predict that there will be numerous issues involved with the disclosure of confidential business information under these amendments, if the Minister were ever to exercise those powers. Although litigants are entitled to production of the documents relevant to the matters at issue in a product liability claim, these are not provided until after they have pleaded and are sometimes provided on the basis of certain confidentiality protections. Release by Health Canada of a company's confidential business information could provide potential claimants and their counsel with access to such information at a pre-litigation stage; and may in fact give rise to litigation that might not otherwise have been contemplated.

For the time being, compliance personnel should proactively take steps to ensure that they are onside the new regulatory framework.

Protecting Yourself

Given the potentially increased product liability exposure and the drastically increased liability for fines and punishment under Vanessa's Law, industry participants should take all possible steps to review their compliance programs and document their compliance with the Act.

Especially now that the law permits the Minister to provide third parties with confidential business information without advising the author of that information, it is crucial that all communications with Health Canada be clear and complete. A regulated party may not have the opportunity to explain the context of any given communication to Health Canada to the third party conducting a review or investigation.

Regulated companies should consider the following augmentations to their existing compliance protocols:

  • Take this opportunity to review compliance programs, procedures and internal training to ensure that the company's steps to cultivate a culture of compliance by reinforcing standards are thoroughly documented;
  • Take all possible steps to address potential risks and to confirm the truth of communications to Health Canada, and then ensure those steps are themselves recorded, including minutes of meetings and transcripts of internal interviews;
  • In providing any form of report to Health Canada, budget time for final fact-checking so that the ultimate signatory of the report can be briefed and satisfied that all representations (s)he is making are well founded, ideally leaving time for that individual to make further inquiries if (s)he is not completely satisfied as to the accuracy of his or her report;
  • Co-ordinate communications between jurisdictions to ensure that any communication to Health Canada contains and is consistent with information provided to other regulators globally; and
  • Review each draft communication to Health Canada with an eye to whether it contains all necessary context and revise as necessary to ensure that any potential misinterpretation can be avoided.

The biggest news with respect to Vanessa's Law, however, is yet to come: in the form of further regulations and the policy direction of Health Canada once it has the opportunity to exercise its new powers. We will continue to follow these developments and report in this newsletter as events warrant.

Keeping You Up-To-Date on Consumer Product Regulation: What's New With The Canada Consumer Product Safety Act?

By Emily Larose

Here's what's new with the Canada Consumer Product Safety Act...

  1. Increased Transparency in New Summary Reports: As part of Health Canada's stated ongoing commitment to transparency, it has announced that it will be publishing the following summary reports on its website going forward:

    Consumer Product Enforcement Safety Reports

    These reports will provide information on products that Health Canada has inspected. They will identify which did and (more significantly) which did not meet applicable safety standards.  These reports will identify the brand, product name and the responsible establishment, the nature of the non-compliance as well as any corrective action taken. Health Canada has advised that its inspections will focus mostly on children's products and product categories with a high history of non-compliance.

    Quarterly Consumer Product Safety Incident Summary Reports

    These reports will provide statistical information about the incident reports received by Health Canada over the previous quarter.  It is important to note that these reports will not identify any specific products, brands or companies. For Q2 2014, Health Canada reports that 432 incident reports were filed, 171 of which included an injury. The largest percentage of reports received related to housewares (33%), followed by appliances (15%) and children's products (12%). 

  2. Insight into Health Canada's Risk Assessment Processes: in December, Health Canada published its Risk Assessment Framework outlining the manner in which it triages, prioritizes and manages reports. This process includes, among other things:

    • Analysis of whether the report is properly made under the CCPSA;
    • Analysis of whether (on a preliminary basis) it appears from the report that a more thorough risk assessment is required;
    • Identification and characterization of the hazard;
    • Estimation of the probability and severity of exposure to the hazard; and
    • Integration of the risk assessment information to characterize the risk and determine risk management options, if appropriate.  
  3. Do You Know Where Your Children Are (Sleeping)?: Health Canada has released a guidance on the classification of cribs, cradles, bassinets and related products. Click here for details.


1 2015 BCCA 26> [Charlton].

2 "Devices" is an exhaustively defined term under the new amendments: see Section 2 of the Food and Drugs Act, as amended.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Carly Cohen
Erin Craddock
Peter Henein
Christopher Horkins
Emily Larose
Stephanie Voudouris
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions